ADHD Alcobra Ltd.

1.25
+0.02  (1.63%)
Previous Close 1.23
Open 1.22
Price To book 0.64
Market Cap 34.45M
Shares 27,562,000
Volume 455,736
Short Ratio 0.81
Av. Daily Volume 778,586

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 17, 2017 - failed to meet primary endpoint.
MDX (Metadoxine Extended Release (MG01CI))
Adult ADHD
Phase 2b data released March 2015. Secondary cognitive measures did not produce statistically significant results.
MDX (Metadoxine Extended Release (MG01CI))
Pediatric ADHD
Phase 2 trial did not meet endpoints - June 2015.
MDX (Metadoxine Extended Release (MG01CI))
Fragile X Syndrome

Latest News

  1. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alcobra, Ltd., and Encourages Investors with Losses to Contact the Firm
  2. Lifshitz & Miller LLP Files Class Action Lawsuit against Alcobra, Ltd.
  3. Blog Coverage Ardelyx Reports Positive Data for the Treatment for Hyperphosphatemia in Patients with End-Stage Renal disease
  4. Edited Transcript of ADHD earnings conference call or presentation 15-Feb-17 1:30pm GMT
  5. Alcobra reports 4Q loss
  6. Alcobra reports 4Q loss
  7. Q4 2016 Alcobra Ltd Earnings Release - 08:30 am ET
  8. Alcobra Announces Fourth-Quarter and Full-Year 2016 Financial Results and Provides Corporate Update
  9. Alcobra Ltd. to Release Fiscal 2016 Financial Results and Participate at the BIO CEO & Investor Conference in New York
  10. Alcobra Reports on Productive FDA Meeting for New Lead Product Candidate for ADHD
  11. Are Options Traders Betting on a Big Move in Alcobra (ADHD) Stock?
  12. INVESTOR ALERT: Lundin Law PC Announces an Investigation of Alcobra, Ltd. and Encourages Investors with Losses to Contact the Firm
  13. Lifshitz & Miller Law Firm Announces Investigation of Alcobra Ltd., Egalet Corporation, Sanderson Farms, Inc., Surgical Care Affiliates, Inc., State Street Corporation, Tenet Healthcare Corp., Vista Outdoor Inc. and Zagg Inc.
  14. Faster FDA Approval Process Could Ignite These Biotech Stocks in 2017
  15. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Alcobra, Ltd., and Encourages Investors to Contact the Firm
  16. Glancy Prongay & Murray LLP Commences Investigation on Behalf of Alcobra Ltd. Investors
  17. Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA
  18. Alcobra Leads Biotech Movers Early Friday
  19. SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Alcobra, Ltd. and Encourages Investors with Losses to Contact the Firm
  20. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Alcobra Ltd.